Evogene (NASDAQ: EVGN) reported Q3 EPS of ($0.31), $0.12 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $310 thousand versus the consensus estimate of $575 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.